These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 33558711

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.
    Steenbruggen TG, van Seijen M, Janssen LM, van Ramshorst MS, van Werkhoven E, Vrancken Peeters MTDF, Wesseling J, Lips EH, Sonke GS.
    Clin Cancer Res; 2019 Aug 15; 25(16):4985-4992. PubMed ID: 31076546
    [Abstract] [Full Text] [Related]

  • 3. Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma.
    Hamy AS, Lam GT, Laas E, Darrigues L, Balezeau T, Guerin J, Livartowski A, Sadacca B, Pierga JY, Vincent-Salomon A, Coussy F, Becette V, Bonsang-Kitzis H, Rouzier R, Feron JG, Benchimol G, Laé M, Reyal F.
    Breast Cancer Res Treat; 2018 Jun 15; 169(2):295-304. PubMed ID: 29374852
    [Abstract] [Full Text] [Related]

  • 4. Comparison of Breast Cancer Staging Systems After Neoadjuvant Chemotherapy.
    Kantor O, Laws A, Pastorello RG, King C, Wong S, Dey T, Schnitt S, King TA, Mittendorf EA.
    Ann Surg Oncol; 2021 Nov 15; 28(12):7347-7355. PubMed ID: 33956276
    [Abstract] [Full Text] [Related]

  • 5. Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy.
    Hamy AS, Darrigues L, Laas E, De Croze D, Topciu L, Lam GT, Evrevin C, Rozette S, Laot L, Lerebours F, Pierga JY, Osdoit M, Faron M, Feron JG, Laé M, Reyal F.
    PLoS One; 2020 Nov 15; 15(6):e0234191. PubMed ID: 32579551
    [Abstract] [Full Text] [Related]

  • 6. Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.
    Pinard C, Debled M, Ben Rejeb H, Velasco V, Tunon de Lara C, Hoppe S, Richard E, Brouste V, Bonnefoi H, MacGrogan G.
    Breast Cancer Res Treat; 2020 Jan 15; 179(1):11-23. PubMed ID: 31529299
    [Abstract] [Full Text] [Related]

  • 7. Assessment of residual cancer burden and survival in neoadjuvant chemotherapy of inoperable stage III breast cancer: A ten-year follow-up analysis in Vietnam.
    Pham HK, Le TD, Nguyen TP, Le TU, Ta HH, Nguyen VC.
    Pathol Res Pract; 2024 Feb 15; 254():155099. PubMed ID: 38244433
    [Abstract] [Full Text] [Related]

  • 8. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
    Miglietta F, Dieci MV, Tsvetkova V, Griguolo G, Vernaci G, Menichetti A, Faggioni G, Giarratano T, Mioranza E, Genovesi E, Cumerlato E, Bottosso M, Saibene T, Michieletto S, Lo Mele M, Conte P, Guarneri V.
    Oncologist; 2020 Sep 15; 25(9):e1355-e1362. PubMed ID: 32618068
    [Abstract] [Full Text] [Related]

  • 9. Neo-Bioscore in Guiding Post-surgical Therapy in Patients With Triple-negative Breast Cancer Who Received Neoadjuvant Chemotherapy.
    Hasegawa Y, Matsubara N, Kogawa T, Naito Y, Harano K, Hosono A, Onishi T, Hojo T, Shimokawa M, Mukohara T.
    In Vivo; 2021 Sep 15; 35(2):1041-1049. PubMed ID: 33622900
    [Abstract] [Full Text] [Related]

  • 10. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
    Resende U, Cabello C, Ramalho SOB, Zeferino LC.
    BMC Cancer; 2019 Jun 17; 19(1):601. PubMed ID: 31208353
    [Abstract] [Full Text] [Related]

  • 11. Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden.
    Asano Y, Kashiwagi S, Goto W, Takada K, Takahashi K, Hatano T, Noda S, Takashima T, Onoda N, Tomita S, Motomura H, Ohsawa M, Hirakawa K, Ohira M.
    BMC Cancer; 2017 Dec 28; 17(1):888. PubMed ID: 29282021
    [Abstract] [Full Text] [Related]

  • 12. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
    Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, I-SPY 2 Trial Consortium, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF.
    Lancet Oncol; 2022 Jan 28; 23(1):149-160. PubMed ID: 34902335
    [Abstract] [Full Text] [Related]

  • 13. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
    Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, Rendi M, Sahoo S, Ocal IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace AM, Forero-Torres A, Ellis E, Albain KS, Murthy RK, Boughey JC, Liu MC, Haley BB, Elias AD, Clark AS, Kemmer K, Isaacs C, Lang JE, Han HS, Edmiston K, Viscusi RK, Northfelt DW, Khan QJ, Leyland-Jones B, Venters SJ, Shad S, Matthews JB, Asare SM, Buxton M, Asare AL, Rugo HS, Schwab RB, Helsten T, Hylton NM, van 't Veer L, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ.
    JAMA Oncol; 2021 Nov 01; 7(11):1654-1663. PubMed ID: 34529000
    [Abstract] [Full Text] [Related]

  • 14. Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors.
    Yi M, Lin H, Bedrosian I, Shen Y, Hunt KK, Chavez-MacGregor M, King TA, Mittendorf EA.
    Ann Surg Oncol; 2020 Feb 01; 27(2):359-366. PubMed ID: 31667721
    [Abstract] [Full Text] [Related]

  • 15. The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy.
    Xu X, Zhao W, Liu C, Gao Y, Chen D, Wu M, Li C, Wang X, Song X, Yu J, Liu Z, Yu Z.
    BMC Cancer; 2024 Jan 02; 24(1):13. PubMed ID: 38166846
    [Abstract] [Full Text] [Related]

  • 16. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
    Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN.
    J Clin Oncol; 2017 Apr 01; 35(10):1049-1060. PubMed ID: 28135148
    [Abstract] [Full Text] [Related]

  • 17. Validation of the CPS+EG and Neo-Bioscore staging systems after preoperative systemic therapy for breast cancer in a single center in China.
    Xu L, Duan X, Zhou B, Liu Y, Ye J, Liu Z, Ma C, Zhang H, Zhang S, Zhang L, Zhao J, Cheng Y.
    Breast; 2018 Aug 01; 40():29-37. PubMed ID: 29677568
    [Abstract] [Full Text] [Related]

  • 18. Incorporation of Treatment Response, Tumor Grade and Receptor Status Improves Staging Quality in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Bergquist JR, Murphy BL, Storlie CB, Habermann EB, Boughey JC.
    Ann Surg Oncol; 2017 Nov 01; 24(12):3510-3517. PubMed ID: 28828583
    [Abstract] [Full Text] [Related]

  • 19. The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment.
    Mittendorf EA, Vila J, Tucker SL, Chavez-MacGregor M, Smith BD, Symmans WF, Sahin AA, Hortobagyi GN, Hunt KK.
    JAMA Oncol; 2016 Jul 01; 2(7):929-36. PubMed ID: 26986538
    [Abstract] [Full Text] [Related]

  • 20. Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems.
    Choi M, Park YH, Ahn JS, Im YH, Nam SJ, Cho SY, Cho EY.
    Breast Cancer Res Treat; 2016 Dec 01; 160(3):475-489. PubMed ID: 27730423
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.